Astrana Health holders back 2024 equity plan
Astrana Health, Inc. reported results from its 2026 Annual Meeting of Stockholders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Astrana Health, Inc. reported results from its 2026 Annual Meeting of Stockholders. Stockholders approved the Amended and Restated 2024 Equity Incentive Plan, which increases the shares of common stock reserved for issuance by 1,000,000 shares and extends the plan’s term until March 24, 2036. All director nominees were elected and the appointment of the independent registered public accounting firm was ratified. An advisory vote on executive compensation passed, and the equity plan received strong support, with 34,679,879 votes in favor. The meeting had a quorum, with 43,772,595 shares represented, about 78.6% of the 55,713,532 shares outstanding as of the record date.
8-K Event Classification
3 items: 5.02, 5.07, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Equity plan share increase: 1,000,000 shares
Plan term end date: March 24, 2036
Shares outstanding on record date: 55,713,532 shares
+5 more
8 metrics
Equity plan share increase
1,000,000 shares
Additional common shares reserved under Amended and Restated 2024 Equity Incentive Plan
Plan term end date
March 24, 2036
Expiration of Amended and Restated 2024 Equity Incentive Plan
Shares outstanding on record date
55,713,532 shares
Common stock outstanding as of April 14, 2026 record date
Shares represented at meeting
43,772,595 shares
Shares present in person or by proxy at 2026 Annual Meeting (about 78.6% of eligible votes)
Equity plan approval votes for
34,679,879 votes
Votes in favor of Proposal 4 approving the 2024 Plan
Say-on-pay approval votes for
34,119,199 votes
Votes in favor of advisory executive compensation proposal
Auditor ratification votes for
43,722,509 votes
Votes supporting ratification of independent registered public accounting firm
Meeting participation rate
78.6%
Approximate percentage of total outstanding eligible votes represented at meeting
Key Terms
Amended and Restated 2024 Equity Incentive Plan, broker non-votes, advisory vote on executive compensation, independent registered public accounting firm, +1 more
5 terms
Amended and Restated 2024 Equity Incentive Plan financial
"approved the Astrana Health, Inc. Amended and Restated 2024 Equity Incentive Plan"
broker non-votes financial
"Kenneth Sim, M.D. ... 1,959,958 ... 8,356,118 broker non-votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
advisory vote on executive compensation financial
"Proposal 3. Advisory Vote on Executive Compensation"
A non-binding shareholder vote allowing investors to approve or reject the pay packages and compensation policies for a company’s top executives. It matters because the outcome tells the board whether owners are satisfied with executive pay and can prompt changes in policy or leadership much like a customer survey prompts a company to adjust its product — signaled approval can support management credibility, while rejection may increase scrutiny and affect investor confidence.
independent registered public accounting firm financial
"Ratification of Appointment of Independent Registered Public Accounting Firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
record date financial
"At the close of business on April 14, 2026, the record date for the Annual Meeting"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Astrana Health (ASTH) stockholders approve at the 2026 annual meeting?
Astrana Health stockholders approved the Amended and Restated 2024 Equity Incentive Plan. The plan increases shares reserved for equity awards by 1,000,000 and extends the plan’s term to March 24, 2036, supporting ongoing stock-based compensation and incentives.
What was the quorum and turnout at Astrana Health’s 2026 Annual Meeting?
At the 2026 Annual Meeting, 43,772,595 shares were present in person or by proxy. This represented approximately 78.6% of the 55,713,532 outstanding shares, meaning the meeting achieved a valid quorum for conducting official stockholder business.
Did Astrana Health (ASTH) stockholders approve executive compensation in 2026?
Yes. In the advisory vote on executive compensation, 34,119,199 votes were cast for, 1,209,072 against, and 88,206 abstained. There were 8,356,118 broker non-votes, but the proposal passed based on votes cast for and against compensation.
How did Astrana Health stockholders vote on the 2024 Equity Incentive Plan?
For the 2024 Equity Incentive Plan, 34,679,879 votes were in favor, 701,303 against, and 35,295 abstained, with 8,356,118 broker non-votes. The strong “for” vote resulted in approval of the amended and restated equity incentive plan.
Was Astrana Health’s independent auditor ratified at the 2026 meeting?
Yes. Stockholders ratified the appointment of Astrana Health’s independent registered public accounting firm with 43,722,509 votes for, 19,566 against, and 30,520 abstentions. There were no broker non-votes on this proposal, reflecting broad support for the auditor.
AI-generated analysis. How Rhea-AI works. Not financial advice.
